Pediatrix Medical Group, Inc.

Health Care
Hospital/Nursing Management
www.pediatrix.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.30B
PE -13
Debt $636.17M
Cash $229.94M
EV $1.71B
FCF $195.23M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$99.07M
EBIT	-$68.71M
ROE	-13%
ROA	-3%
FCF	$195.23M
Equity	$764.94M
Growth Stability	-492%
PE	-13.12
PEG	-7.03
PB	1.7
P/FCF	6.66
P/S	0.65
Price/Cash	0.18
Debt/Equity	0.83
Debt/FCF	3.26
Net Margins	-5%
Op. Margins	-3%
Earnings CAGR	-5%
Sales Growth YoY	1%
Sales Growth QoQ	-2%
Sales CAGR	-8%
FCF CAGR	-16%
Equity CAGR	-16%
Earnings Stability	0.13
Earnings Growth YoY	-125%
Earnings Growth QoQ	57%

Earnings CAGR 5Y	2%
Sales CAGR 5Y	-3%
FCF CAGR 5Y	-12%
Equity CAGR 5Y	-3%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
FCF CAGR 3Y	11%
Equity CAGR 3Y	-6%
Market Cap	$1.30B
Revenue	$2.01B
Assets	$2.15B
Total Debt	$636.17M
Cash	$229.94M
Shares Outstanding	83.25M
EV	1.71B
Earnings Score	5%
Moat Score	8%
Safety Score	58%
Final Score	24%
Working Capital	205.5M
Current Ratio	1.47
Shares Growth 3y	-0%
Equity Growth QoQ	4%
Equity Growth YoY	-10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment, which is physician services. Mednax generates roughly half of its revenue from the women's and children's services provided, and also roughly half of the company's total revenue is earned in the United States.

SEC Filings

Direct access to Pediatrix Medical Group, Inc. (MD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Pediatrix Medical Group, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Pediatrix Medical Group, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%

Stability 13%

loading chart...

Pediatrix Medical Group, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Pediatrix Medical Group, Inc..

Years

Calculation mode

= $723M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$195M	$164M	$138M	$116M	$98M	$82M	$69M	$58M	$49M	$41M	$34M	$345M
DCF		$149M	$114M	$87M	$67M	$51M	$39M	$30M	$23M	$17M	$13M	$133M
Value	$723M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	12%	10%	9%	7%	-43%	-46%	7%	3%	-3%	-5%	-5%
ROA	-	11%	8%	8%	-27%	3%	7%	7%	0%	-3%	-3%
ROE	-	12%	10%	9%	-100%	-107%	15%	7%	-7%	-13%	-13%

Bad Net Margins (-4.92%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	4.29	4.03	8.25	5.56	9.95	12.3	4.32	5.7	3.26	3.26
Debt over Equity	0.53	0.63	0.61	0.64	1.17	2.34	1.12	0.74	0.76	0.83	0.83
Growth Stability	-	-	-	82%	-492%	-	-	-	-	-217%	-492%

Neutral Debt/FCF ratio (3.26)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.83)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-492%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	15%	9%	5%	-4%	-51%	10%	3%	1%	1%	-3%
Earnings YoY growth	-	-3%	-1%	-16%	-658%	-47%	-116%	-49%	-191%	64%	2%
Equity YoY growth	-	13%	11%	1%	-51%	-50%	20%	-1%	-5%	-10%	-3%
FCF YoY growth	-	18%	14%	-48%	31%	-44%	-54%	87%	-26%	73%	-12%